Auranofin is an oral gold compound used for the treatment of rheumatoid arthritis (RA). The use of auranofin has declined in the past few years, perhaps due in part to conflicting results from different studies.
Activation of the NRF2 transcription factor shows promise as a potential treatment approach for non-alcoholic fatty liver disease (NAFLD), a condition associated with oxidative stress and liver damage. By screening FDA-approved drugs, researchers identified six compounds that enhanced NRF2 activity and demonstrated protective effects against oxidative stress and lipid accumulation.
Researchers at Baylor College of Medicine and collaborating institutions discovered that the rheumatoid arthritis drug auranofin can potentially be repurposed to improve diabetes-associated symptoms.
In a new ISCIENCE journal study, scientists identified an FDA-approved NF-κB inhibitor, Auranofin, which can also control inflammation.
The gold complex auranofin has traditionally been used for treating rheumatism but is also being evaluated as a treatment for certain forms of cancer.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produces inflammatory cytokine storms. But an FDA-approved anti-rheumatic drug, Auranofin, used to treat autoimmune and infectious diseases, may also help serve as an antiviral treatment for COVID-19 infection.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 3.42 million deaths worldwide. Despite the fact that there are vaccines for SARS-CoV-2, the emergence of new variants and the lack of adequate treatments have encouraged the search for new ways to combat this disease more effectively.
Using samples of small cell lung tumors, a research team led by biologist Dr Silvia von Karstedt has discovered two new ways to induce tumor cell death. One of two subsets of tumor cells can be targeted by activating ferroptosis: iron-dependent cell death caused by oxidative stress
Neuroblastoma is a cancer that develops in nerve tissue, most commonly in the glands around the kidneys. The gene MYCN is overexpressed in 20-25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a considerable percentage of pediatric cancer-related deaths.
A new study published in the pre-print server bioRxiv* explores the viral enzyme PLpro, encoded in the nonstructural protein nsp3, and its inhibitors. T
A research team led by Professor Hongzhe SUN, Chair Professor from the Department of Chemistry, Faculty of Science, in collaboration with Dr Pak-Leung HO, Director of the HKU Carol Yu Centre for Infection from the Department of Microbiology, Li Ka Shing Faculty of Medicine.
The fight against bacterial infections, especially those caused by resistant pathogens, is in full swing with the search for new antibiotic agents.
A drug called auranofin, approved for the treatment of rheumatoid arthritis, effectively inhibits severe acute respiratory syndrome coronavirus (SARS-CoV-2) in laboratory conditions, as described in a new study by Georgia State University researchers.
Brown University researchers have developed a new antibacterial coating for intravascular catheters that could one day help to prevent catheter-related bloodstream infections, the most common type of hospital-acquired infection.
Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?
Scientists at EPFL and NTU have discovered that combining an anticancer drug with an antirheumatic produces improved effects against tumors. The discovery opens a new path for drug-drug synergy.
Researchers at Mayo Clinic have identified a genetic promoter of cancer that drives a major form of lung cancer.
Researchers on Mayo Clinic's Florida campus have shut down one of the most common and lethal forms of lung cancer by combining the rheumatoid arthritis drug auranofin with an experimental targeted agent.
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Researchers developed a promising metal-based compound that destroys kidney cancer cells, while leaving normal cells unharmed. The findings may provide a new way of treating kidney cancer, opening the potential for more potent and less toxic therapies that would give cancer patients a better quality of life.
Two UCSF teams have received a total of $16 million from the Bill & Melinda Gates Foundation to study new ways to significantly reduce childhood mortality and disease in developing nations.